ASCO Annual Meeting | Conference

Dr. Mitchell on a Subgroup Analysis of the VELOUR Trial

June 26th 2013

Edith Mitchell, MD, FACP, from Thomas Jefferson University, gives an overview of the North American subgroup analysis of the VELOUR trial.

Dr. Chang on the TRINOVA-1 Trial in Ovarian Cancer

June 25th 2013

David D. Chang, MD, PhD, head of global oncology development at Amgen, discusses the design of the TRINOVA-1 trial in ovarian cancer.

Dr. Robertson on Olaparib for Serous Ovarian Cancer

June 24th 2013

Jane Robertson, MD, Global Product Vice President for olaparib at AstraZeneca, discusses a trial looking at olaparib for patients with serous ovarian cancer.

Dr. Weber Explores Nivolumab in Advanced Melanoma

June 21st 2013

Jeffrey S. Weber, MD, PhD, from the Moffitt Cancer Center and Research Institute, describes a single institution phase I/II trial exploring the anti-PD-1 antibody nivolumab in combination with a peptide vaccine for patients with unresectable melanoma.

Dr. Hudis on the CALGB 40601 Study in Breast Cancer

June 20th 2013

Clifford A. Hudis, MD, chief of the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center in New York, discusses the findings of the CALGB 40601 study in breast cancer.

Dr. Shore on Immunotherapies for Prostate Cancer

June 20th 2013

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, gives an overview of the development of immunotherapies for patients with prostate cancer.

Dr. Wolchok on Concurrent Ipilimumab and Nivolumab

June 19th 2013

Jedd D. Wolchok, MD, PhD, from the Memorial Sloan-Kettering Cancer Center, discusses a phase I trial exploring the combination of the anti-PD-1 antibody nivolumab and ipilimumab, a CTLA-4 inhibitor, for patients with advanced melanoma.

Dr. Goede on the Results from the Phase III CLL11 Trial

June 19th 2013

Valentin Goede, MD, Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany, discusses the findings of the phase III CLL11 trial.

Dr. Lesser on the Background of the RTOG 0424 Study

June 17th 2013

Glenn J. Lesser, MD, discusses the background of the RTOG 0424 study, which analyzed temozolomide in high-risk low-grade gliomas.

Dr. Aft on Disseminating Tumor Cells and Prognosis

June 14th 2013

Rebecca L. Aft, MD, PhD, discusses the identification of patients with breast cancer at high risk of recurrent disease development by detection of HER2-positive disseminated tumor cells in bone marrow of patients with HER2-negative tumors.

Dr. Camidge on Crizotinib as a ROS1 Inhibitor in NSCLC

June 13th 2013

D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the use of crizotinib as a ROS1 inhibitor in non-small cell lung cancer (NSCLC).

Dr. Hutson on Tivozanib for Renal Cell Carcinoma

June 13th 2013

Thomas Hutson, DO, PharmD, discusses tivozanib for the treatment of advanced renal cell carcinoma (RCC).

Dr. Saenger on Combining Targeted and Immune Agents

June 12th 2013

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the idea of combining targeted and immune agents.

Dr. Figlin on Sequencing mTOR Inhibitors and TKIs in RCC

June 12th 2013

Robert Figlin, MD, FACP, discusses the sequencing of mTOR inhibitors and tyrosine kinase inhibitors in renal cell carcinoma.

Dr. Van Tine on Arginine Deiminase for Sarcomas

June 11th 2013

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses the use of arginine deiminase (ADI-PEG20) for the treatment of sarcomas.

Dr. Lehman Discusses the Use of Breast MRI

June 10th 2013

Constance D. Lehman, MD, PhD, Vice Chair, Radiology Department, University of Washington School of Medicine, Medical Director, Imaging, Seattle Cancer Care Alliance, discusses the use of breast MRI.

Dr. Andtbacka Reviews the Efficacy of T-VEC in Melanoma

June 7th 2013

Robert Andtbacka, MD, from the Huntsman Cancer Institute, provides an overview of the phase III OPTiM trial that explored treatment with talimogene laherparepvecin patients with advanced melanoma.

Dr. Rutgers Compares ART or ALND in Breast Cancer

June 7th 2013

Emiel J. Rutgers, MD, surgical oncologist, Netherlands Cancer Institute, Amsterdam, discusses a study analyzing radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients.

Novel Hsp Inhibitor May Offer NSCLC Salvage Option

June 7th 2013

Salvage therapy combining the novel heat shock protein 90 inhibitor ganetespib with docetaxel significantly improved overall survival in some patients with non–small cell lung cancer.

Dr. Finn on the Future of Palbociclib in Breast Cancer

June 6th 2013

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes the potential impact of the cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in the treatment of patients with ER-positive metastatic breast cancer.